Skip to main navigation
Skip to search
Skip to main content
OSU Center for Health Sciences Research Profiles Home
Help & Contact
Link opens in a new tab
Search content at OSU Center for Health Sciences Research Profiles
Home
Profiles
Research units
Projects
Research output
Prizes
Activities
Press/Media
Assessing Risk/Benefit Profile of Lapatinib in Clinical Trials
Alec Young
,
Trevon Jelinek
,
Griffin Hughes
, Brooke Gardner
,
Chase Ladd
,
Andriana Peña
,
Ryan McIntire
,
Raymon Carabajal
, Jordan Tuia
, Alyson Haslam
, Vinay Prasad
,
Matt Vassar
COM Entering Class of 2022
COM Entering Class of 2020
Residency Programs
Office of Medical Student Research
Research Opportunities
Psychiatry and Behavioral Sciences
Research output
:
Contribution to conference
›
Poster
›
peer-review
31
Downloads (Pure)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Assessing Risk/Benefit Profile of Lapatinib in Clinical Trials'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Clinical Trials
100%
Risk-benefit
100%
Lapatinib
100%
Assessing Risk
100%
Breast Cancer
33%
Combination Therapy
33%
Overall Survival
22%
Adverse Event Rates
22%
Response Rate
11%
PubMed
11%
Adverse Events
11%
Embase
11%
Solid Tumors
11%
Tolerability
11%
Cochrane
11%
Positive Outcomes
11%
Progression-free Survival
11%
Trial Characteristics
11%
Oncologic
11%
Advanced Breast Cancer
11%
Objective Response Rate
11%
Metastatic Breast Cancer
11%
FDA-approved Drugs
11%
Approved Indication
11%
Risk-benefit Analysis
11%
Repurposing
11%
Solid Cancer
11%
Median Progression-free Survival
11%
Off-label Indications
11%
Drug Manufacturer
11%
Novel Chemotherapy
11%
Extended Indications
11%
Objective Response
11%
RECIST Criteria
11%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Lapatinib
100%
Breast Cancer
44%
Adverse Event
33%
Combination Therapy
33%
Malignant Neoplasm
22%
Progression Free Survival
22%
Overall Survival
22%
Chemotherapy
11%
Tolerability
11%
Solid Malignant Neoplasm
11%
Metastatic Breast Cancer
11%
Pharmaceutical Manufacturing
11%